Article Text
Abstract
Objective Patients with multimorbidity may carry a large symptom burden. Symptoms are often what drive patients to seek healthcare and they also assist doctors with diagnosis. We examined whether symptom burden is additive in people with multimorbidity compared with people with a single morbidity.
Design This is a longitudinal cohort study drawing on questionnaire and Danish national registry data. Multimorbidity was defined as having diagnoses from at least two out of ten morbidity groups. Associations between morbidity groups and symptom burden were estimated with multivariable models.
Participants In 2012, 47 452 participants from the Danish Symptom Cohort answered a questionnaire about symptoms (36 symptoms in total), including whether symptoms were affecting their daily activities (impairment score) and their worries about present symptoms (worry score) (the highest score among the 36 symptoms on a 0–4 scale).
Main outcome measure The primary outcome was symptom burden.
Results Participants without morbidity reported 4.77 symptoms (out of 36 possible). Participants with one, two or three morbidities reported more symptoms than patients without morbidity (0.95 (CI 0.86 to 1.03), 1.87 (CI 1.73 to 2.01) and 2.89 (CI 2.66 to 3.12), respectively). Furthermore, they reported a higher impairment score (0.36 (0.32 to 0.39), 0.65 (0.60 to 0.70) and 1.06 (0.98 to 1.14)) and a higher worry score (0.34 (0.31 to 0.37), 0.62 (0.57 to 0.66) and 1.02 (0.94 to 1.10)) than participants without morbidity. In 45 possible combinations of multimorbidity (participants with two morbidities), interaction effects were additive in 37, 41 and 36 combinations for the number of symptoms, impairment score and worry score, respectively.
Conclusion Participants without morbidity reported a substantial number of symptoms. Having a single morbidity or multimorbidity resulted in approximately one extra symptom for each extra morbidity. In most combinations of multimorbidity, symptom burden was additive.
- epidemiology
- primary care
- public health
Data availability statement
Data may be obtained from a third party and are not publicly available. Data are stored at Statistics Denmark. To share data, approvals are required from the Danish Data Protection Agency and The Danish Health Data Authority.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Strengths and limitations of this study
This study combines high-quality data from Danish national registries and questionnaire data from the background population.
The questionnaire used in this study draws on a breadth of symptoms indicative of both serious and less harmful diseases.
The selection of symptoms in the questionnaire is not exhaustive, which may induce artificial differences between morbidities; nevertheless, this does not bias synergy estimates.
Multimorbidity is defined as having two or more morbidities; in this study, a morbidity is defined as having one or more chronic diagnoses from one of ten predefined morbidity groups: lung, musculoskeletal, endocrine, mental health, cancer, neurological, gastrointestinal, cardiovascular, genitourinary and sensory.
Introduction
Multimorbidity, most often defined as the co-occurrence of two or more chronic diseases,1 affects mental health,2 quality of life3 and survival,4 and patients with multimorbidity often struggle to manage their symptoms.5 Symptoms play a major part in how people self-rate their health.6 Factors like disability, duration and feelings of vulnerability are important drivers for how a sensation gradually turns into a symptom,7 where interpretations of danger and intensity can be decisive in making a contact with healthcare.8 Hence, the presence of symptoms is important for doctors to be able to formulate a diagnosis, and thereby symptoms become a pathway through which a person becomes a patient.9 Symptoms, however, can be difficult to explain and doctors may focus solely on relieving them.9 10 Additionally, diagnoses are not always helpful in explaining symptom experiences,11 and having one diagnosis increases the risk of being diagnosed with other diseases.12 Patients with multimorbidity report a considerable symptom burden,5 13 and more focus on symptom management in multimorbidity has been suggested.14 Therefore, an understanding of the relationship between diagnoses and symptom burden is warranted, and especially an understanding of how symptom burden is experienced when diagnoses occur in multiples, that is, multimorbidity. The aim of this study was to explore symptom burden in patients with one of ten morbidities compared with symptom burden in patients with multimorbidity. We hypothesised that symptom burden in multimorbidity was additive, that is, symptoms in patients with multimorbidity were equivalent to the sum of the symptoms attributable to the single morbidities.
Methods
Study design and population
The study was a longitudinal cohort study. Participants were from the Danish Symptom Cohort, a population-based study conducted in Denmark in June–December 2012. People invited to participate in the study were living in Denmark on 1 January 2012 (baseline). Of 100 000 adults (≥20 years) randomly selected from the general Danish population, 95 253 were eligible and invited to participate (figure 1). Of these, 49 706 (52.2%) completed the study questionnaire (online supplemental file 1).15
Supplemental material
All Danish-born and immigrant populations in Denmark have a unique personal identification number in the Danish Civil Registration System.16 The register contains information about age, sex, vital status and so on, and enables information from different Danish registries to be linked. Information on diagnoses leading to either inpatient or outpatient care in the hospital sector was collected from the Danish National Patient Register,17 the Danish Cancer Registry18 and the Danish Psychiatric Central Research Register.19 Thus, only diagnoses from secondary care were included in the study. Information on education,20 work status,21 family income,22 assets (banks, stocks, bonds and housing),22 degree of urbanisation and cohabitation status was obtained from the nationwide registries at baseline.
Symptom data
The Danish Symptom Cohort was established to investigate symptom experience in the general population and healthcare-seeking in relation to general practice. According to the random sample selected from the Danish population, the cohort included both healthy people and people with diseases. Several articles have been published with data from the cohort.23–25 The focus of the present study was symptom burden in people with multimorbidity and variables for the study were selected accordingly.23 The median age of the participants in the Danish Symptom Cohort was 52 years (IQR 40–64) and for non-participants it was 50 years (IQR 36–67). The respondents were reasonably representative of the study sample, but non-respondents were more often men, unmarried, with lower education, lower income level and with a generally looser attachment to the labour market.
The survey consisted of a web-based questionnaire supported by a telephone interviewer if warranted. The questionnaire was electronic and designed so that it was not possible to skip items, and therefore there were no missing values for those who completed it. The process of developing the questionnaire has been described by Rasmussen et al.15 The questionnaire had five domains: three about experience of symptoms and how participants acted on them, and two about factors related to symptom experience and healthcare-seeking behaviour (online supplemental file 1). The questionnaire included 38 general symptoms, as well as 2 specific symptoms for men and 4 for women (44 symptoms in total). The first sentence in the questionnaire was ‘We are interested to hear if you have experienced any bodily sensations, symptoms, or discomfort within the last four weeks’. For the general symptoms the following phrase was used: ‘Have you experienced any of these within the last 4 weeks?’ Respondents had the opportunity to tick more than one box in a list presenting the 38 general symptoms (online supplemental file 1). Eight symptoms were excluded in the present analyses as six of them were gender-specific (as mentioned above) and would have made comparisons between men and women difficult, and two symptoms ‘coughing up blood’ and ‘blood in vomit’ had low prevalence in the data. Therefore, we included 36 symptoms in the analyses (online supplemental file 2).
Supplemental material
The questionnaire also included questions about how each symptom affected usual daily activities (impairment score) and the participant’s concern about each symptom (worry score): ‘Within the last 4 weeks, to what extent did you experience that the following symptoms or discomfort interfered with your usual daily activities?’ and ‘Within the last 4 weeks, to what extent were you concerned about the following symptoms or discomfort?’ For each symptom, there were five response categories: ‘not at all’, ‘slightly’, ‘moderate’, ‘quite a bit’ and ‘extremely’. The response categories were transformed into a numeric scale (0–4), where the experience rated 4 is worse than the experience rated 1.
Symptom burden
Three components defined symptom burden: (1) number of symptoms (number score 0–36); (2) how symptoms affect usual daily activities (impairment score 0–4 per symptom reported; and (3) concern about the symptoms (worry score 0–4 per symptom reported).
For the impairment score and the worry score, we included the symptom with the highest score in the analyses; for example, if a patient scores 3 for tiredness and scores 1 for dizziness, the overall score is 3. This is because we anticipated that the most burdensome symptoms affect quality of life more heavily than a number of minor symptoms.26
Multimorbidity
Information on diagnoses was retrieved from the nationwide health registries in the 10-year period preceding baseline (1 January 2002–31 December 2011). Participants were excluded if they had not been living continuously in Denmark during this 10-year period. Chronic disease diagnoses were grouped into 10 domains: lung, musculoskeletal, endocrine, mental health, cancer, neurological, gastrointestinal, cardiovascular, genitourinary and sensory. In each domain, relevant diagnoses from the International Classification of Diseases, 10th edition were included (online supplemental file 3). Morbidity is defined as having a diagnosis from one domain, and multimorbidity is defined as having a diagnosis from two or more different domains.27 This definition rests on the assumption that it is more complex and realistic from a physiological and organisational point of view if the patient is living with diagnoses from different domains of the body.27 Often two chronic diagnoses refer to the same disease entity, for example, myocardial infarction and congestive heart failure. Therefore, our definition of multimorbidity relates more closely to how healthcare is organised and it grasps some aspects of complexity to a greater extent than counting individual diagnoses (online supplemental file 3). People who do not have any of the diagnoses included in the 10 domains were considered to have no morbidity.
Supplemental material
Statistical analysis
Symptom burden in people with a single morbidity and multimorbidity was explored using multivariate analyses adjusted for age, sex, socioeconomic status (highest completed education, income, assets and work status), degree of urbanisation, cohabitation status, smoking and alcohol consumption. Excess symptom burden for people with multimorbidity (combinations of two diagnosis domains) was assessed in multivariable linear regression models. For each of the three measures of symptom burden (number of symptoms, impairment score and worry score), the (10×9)/2=45 regression coefficients pertaining to the two-way interactions between diagnosis domains were retained from a multivariable linear regression on all combinations of diagnosis domains, adjusted for the same covariates as mentioned above. These coefficients were directly interpreted as the synergy effect, that is, excess symptom burden associated with having diagnoses from two diagnosis domains relative to the sum of the symptom burden associated with having a diagnosis from the diagnosis domains individually. Analyses were performed using SAS V.9.4.
Patient and public involvement
No patients nor any other members of the public were involved in the design, conduct or reporting of this study.
Informed consent was obtained from all participants.
Results
The study sample consisted of 47 452 people ≥20 years old (figure 1), out of whom 17 227 (36.3%) had a single morbidity and 5652 (11.9%) had multimorbidity (table 1). Overall, 43 228 (91.1%) reported symptoms (table 1 and online supplemental file 4), with 92.8% of people with single morbidity or multimorbidity reporting at least one symptom and 90.2% of people without morbidity reporting at least one symptom. On average, the participants experienced 4.8–7.4 symptoms depending on morbidities within the last 4 weeks (online supplemental table A).
Supplemental material
Supplemental material
Morbidity and symptom burden
Participants without morbidity reported 4.77 symptoms (SD 3.92) on average (online supplemental table A). The more morbidities a participant had, the more symptoms they reported. In multivariable analysis adjusted for confounders, each extra morbidity was associated with approximately one extra symptom (table 2).
Participants without morbidity reported a mean impairment score of 2.74 (SD 1.46). The more morbidities a participant had, the higher their reported impairment score (table 2). In multivariable analysis adjusted for confounders, each extra morbidity was associated with an approximately 0.35 higher impairment score (participants with one, two or three morbidities) than participants without morbidity. However, in participants with four or more morbidities, there was a levelling off in added impairment score with the number of morbidities (table 2).
Participants without morbidity reported a worry score of 2.16 (SD 1.38). The more morbidities, the higher the worry score participants reported (table 2). In multivariable analysis adjusted for confounders, each extra morbidity was associated with an approximately 0.34 higher worry score (participants with one, two or three morbidities) than participants without morbidity. In participants with four or more morbidities, however, there was a levelling off in added worry score for each additional morbidity (table 2).
Multimorbidity and interaction effect of symptom burden
Participants with multimorbidity (confined to participants with two morbidities) were analysed for interaction effects regarding their number of symptoms, impairment score and worry score. We did this to estimate if the symptom burden was additive (equivalent to the sum of two individual diagnoses), infra-additive (less than) or supra-additive (greater than) in specific combinations of multimorbidity.
The number of symptoms reported by participants with specific combinations of multimorbidity is outlined in online supplemental tables A and B and depicted in figure 2. In multivariable analyses adjusted for confounders, the number of symptoms reported by the participants was additive in 37 out of 45 combinations of multimorbidity. The combinations lung–mental health, cancer–heart and cancer–sensory were associated with a supra-additive number of symptoms (online supplemental table C). On the other hand, the combinations lung–musculoskeletal, endocrine–mental health, neurological–mental health, cancer–kidney and heart–kidney were associated with an infra-additive number of reported symptoms (online supplemental table C).
Supplemental material
Supplemental material
Impairment scores as reported by participants with multimorbidity are outlined in online supplemental tables D and E and depicted in figure 3. In multivariable analyses adjusted for confounders, the impairment score was additive in 41 out of 45 combinations of two morbidities. The combination cancer–sensory was associated with a supra-additive impairment score. The combinations lung–gastrointestinal, cancer–kidney and heart–kidney were associated with an infra-additive impairment score.
Supplemental material
Supplemental material
Worry scores as reported by participants with multimorbidity are outlined in online supplemental tables F and G and depicted in figure 4. In multivariable analyses the worry score was additive in 36 out of 45 combinations of two morbidities. The combinations cancer–mental health, cancer–neurological and cancer–sensory were associated with a supra-additive worry score. The combinations lung–musculoskeletal, lung–kidney, endocrine–kidney, cancer–kidney, neurological–kidney and heart–kidney were associated with an infra-additive impairment score.
Supplemental material
Supplemental material
Discussion
Main findings
Participants without morbidity reported a number of symptom experiences (mean 4.8, median 4), and one extra symptom was added with each additional morbidity. Patients with a single morbidity, therefore, reported 5.8 symptoms, patients with three morbidities reported 7.8 symptoms, and so forth. Thus, the number of symptoms was additive with one extra symptom for each extra morbidity.
The same pattern was seen for how the symptoms interfered with the participants’ daily activities and how much the participants were concerned about their symptoms. An impairment score (2.7) and a worry score (2.2) were reported by participants with no morbidity. Each morbidity added approximately 0.3 to the impairment and worry scores (up to three morbidities). Hereafter the impairment and worry scores levelled off to a slow increase with the number of morbidities (four, five and six). Thus, the scores for how symptoms interfered with the participants’ daily activities and how much the participants were concerned about their symptoms were relatively high in participants without morbidity, and the increase in impairment and worry scores was additive for every extra morbidity up to three. Hereafter, each morbidity (from four to seven morbidities) did not add much to the impairment and worry scores.
In regard to symptom burden among specific combinations of multimorbidity, most combinations followed an additive pattern, that is, the reported extra symptom burden in patients with multimorbidity was equivalent to the sum of the symptom burdens attributable to the individual morbidities. However, there were some exceptions to the overall additive pattern, most notably the combination sensory–cancer, where the symptom burden was supra-additive in all three components of symptom burden, and the combinations cancer–kidney and heart–kidney, where all three components of symptom burden were infra-additive. Thus, sensory–cancer seemed to be especially burdensome, whereas cancer–kidney and heart–kidney seemed to be less burdensome than other combinations of multimorbidity.
Comparisons with existing literature
In this study, many participants reported symptoms independent of morbidities. Since symptoms are a main source of information when a doctor establishes a diagnosis9 10 and symptoms are important mediators for healthcare-seeking behaviour,28 the high number of symptoms independent of morbidity could seem unexpected. However, it was earlier shown that only a limited part of experienced symptoms end up being presented to a doctor.23 Furthermore, it highlights the fact that symptoms to some degree are prerequisites of human condition7 in contrast to diagnoses that are created by medicine.10 However, symptoms have been shown to be frequent in the population,28 29 and when interviewed a large number of people reported experiencing symptoms within a 2-week period.30 Furthermore, it is reasonable to believe that symptom burden affects self-rated health,31 32 even though evidence suggests that it is not the symptom itself, but rather limitations on daily activities, worry and treatment burden related to the symptom that affect patients most.33 A person’s self-rated health decreases with the number of chronic diseases they are living with, and this is most pronounced in younger and previously healthy people,34 which is in line with our results.
In this study, we found that the majority of multimorbidity combinations were additive and even had a levelling off effect. This could indicate that the definition of multimorbidity we used is clinically relevant, since the number of symptoms increases with the number of morbidities. While prognosis in multimorbidity is worse than could be predicted by adding the prognoses of individual diseases,35 this is not the case for symptoms, according to the present study. This finding may, however, be explained by the overlap of symptoms between diagnoses. Another explanation could be that diagnoses are more likely to be made when patients have many contacts with the healthcare system.12 This could particularly add to the amount of diagnoses made without symptoms. Furthermore, it is known that older people seem to adapt to chronic conditions with a lower influence on their self-rated health as a result.35
This study shows that a mean of one new symptom is added for each morbidity, indicating that the symptom burden of patients with multimorbidity may be substantial. This may help clinicians to understand why patients with multimorbidity struggle to recognise which symptoms to focus on36 and also help us understand why patients with multimorbidity are sometimes overwhelmed by their symptom burden.5 13 With the number of morbidities they have to live with, multimorbidity can quickly become a complex issue for patients,37 not only because of the burden of symptoms, but also because of the burden of treatment,38 the organisational challenges38 and the demands from everyday life.33
In most combinations of multimorbidity, symptom burden was additive rather than supra-additive. However, there were a few exceptions; for example, the multimorbidity combination sensory–cancer was supra-additive. Patients with multimorbidity combinations that included cancer reported a supra-additive symptom burden, especially regarding their worry score. Cancer has a certain status in the general population as something fatal and cancer alarm symptoms can act as a mediator for making contact with a doctor.31
Participants with multimorbidity that included a kidney morbidity most often reported an infra-additive symptom burden, especially regarding their worry score. This could be explained by the fact that a kidney diagnosis is more likely to come from a laboratory test and general and often reported symptoms such as tiredness. Furthermore, in the kidney domain of our definition of multimorbidity, incontinence was an important and frequent diagnosis, but not necessarily a worrying one.39 40
Strengths and limitations
The population-based cohort and high response rate are strengths of our study,41 as well as the questionnaire containing a breadth of symptoms indicative of both serious and less harmful diseases, and the adjustments for several important factors. The relatively low prevalence of multimorbidity in this study compared with other studies can be explained by the definition based on 10 groups of diagnoses from secondary care.2 42 The nationwide registers have high validity and they require referral to secondary care, thus ensuring that the resulting diagnoses have a certain seriousness.17 18 In Denmark, primary care data on diagnoses are not available. However, we believe our broader definition, in contrast to simple disease counts,27 43 better grasps the burden and complexity of multimorbidity.
The selection of symptoms in the questionnaire is not exhaustive and are not selected in order to represent the morbidity domains; however, they may show preference towards certain domains; for example, there are many urinary tract-related symptoms relative to only a few kidney diagnoses. This may induce artificial differences between diagnoses groups. However, this does not bias the synergy estimates. Furthermore, the presence of diagnoses from secondary care contacts does not allow us to obtain adequate data on diagnosis duration, which could be of importance for symptom experience.44 However, the time limit of 4 weeks in the questionnaire was used to focus on relevant symptoms, while they can still be recalled.15 Finally, we cannot completely rule out that the multimorbidity combinations being supra-additive or infra-additive may be a result of multiple testing.
Implications
It is well known that patients with multimorbidity face challenges in relation to their symptoms,5 and this study shows that symptom burden is, or rapidly becomes, substantial for these patients. Little is known about optimal management of symptoms,14 which underlines the need for increased attention to symptom burden among patients with multimorbidity. Initiatives such as patient diaries, describing the quality of disease management, paying attention to how patients explain their illness in order to understand their stories and life themes,45 and patient involvement in deciding the agenda and achieving realistic goals33 are probably valuable for optimal management. In conclusion, patients with multimorbidity add approximately one extra symptom for each additional morbidity, and symptom burden in these patients is additive, that is, equivalent to the sum of symptoms attributable to the individual morbidity.
Data availability statement
Data may be obtained from a third party and are not publicly available. Data are stored at Statistics Denmark. To share data, approvals are required from the Danish Data Protection Agency and The Danish Health Data Authority.
Ethics statements
Ethics approval
The Danish Symptom Cohort study was approved by the Ethics Committee and the National Board of Health. The Danish Data Protection Agency approved the Danish Symptom Cohort (journal number 2011-41-6651) and approved linkage with other registers (journal number 2015-231-0149). For the present analyses, the Danish Data Protection Agency, Statens Serum Institut and Statistics Denmark approved the use of register data. Administrative register data were anonymised, and reapproval from the Ethics Committee was not needed, nor did we need additional informed consent from the participants.
Acknowledgments
The authors are deeply grateful to Niels de Fine Olivarius for his dedicated support in this work.
References
Supplementary materials
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Footnotes
Contributors TGW designed, wrote and edited the manuscript, researched the data, and contributed to the discussion. VS and DRN performed the analyses, researched the data, contributed to the discussion and reviewed/edited the manuscript. RK-R researched the data, contributed to the discussion and reviewed/edited the manuscript. ADG, DJ and SR made important contributions to the discussion and content and reviewed/edited the manuscript. All authors approved the final version of the manuscript. TGW, VS and DRN have full access to data and take full responsibility for the truthfulness in the data and in the data analyses. TGW is the guarantor of this work.
Funding The study received funding from The Health Foundation (Danish) (grant number 19-B-0173).
Disclaimer The study sponsors had no role in study design, data collection, and analysis or in writing the manuscript.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.